Literature DB >> 16940072

Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Anita Y M Howe1, Huiming Cheng, Ian Thompson, Srinivas K Chunduru, Steve Herrmann, John O'Connell, Atul Agarwal, Rajiv Chopra, Alfred M Del Vecchio.   

Abstract

A new pyranoindole class of small-molecule inhibitors was studied to understand viral resistance and elucidate the mechanism of inhibition in hepatitis C virus (HCV) replication. HCV replicon variants less susceptible to inhibition by the pyranoindoles were selected in Huh-7 hepatoma cells. Variant replicons contained clusters of mutations in the NS5B polymerase gene corresponding to the drug-binding pocket on the surface of the thumb domain identified by X-ray crystallography. An additional cluster of mutations present in part of a unique beta-hairpin loop was also identified. The mutations were characterized by using recombinant replicon variants engineered with the corresponding amino acid substitutions. A single mutation (L419M or M423V), located at the pyranoindole-binding site, resulted in an 8- to 10-fold more resistant replicon, while a combination mutant (T19P, M71V, A338V, M423V, A442T) showed a 17-fold increase in drug resistance. The results of a competition experiment with purified NS5B enzyme with GTP showed that the inhibitory activity of the pyranoindole inhibitor was not affected by GTP at concentrations up to 250 microM. Following de novo initiation, the presence of a pyranoindole inhibitor resulted in the accumulation of a five-nucleotide oligomer, with a concomitant decrease in higher-molecular-weight products. The results of these studies have confirmed that pyranoindoles target the NS5B polymerase through interactions at the thumb domain. This inhibition is independent of GTP concentrations and is likely mediated by an allosteric blockade introduced by the inhibitor during the transition to RNA elongation after the formation of an initiation complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940072      PMCID: PMC1693979          DOI: 10.1128/AAC.00365-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Pre-steady-state kinetics of initiation of transcription by T7 RNA polymerase: a new kinetic model.

Authors:  I Kuzmine; C T Martin
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

Review 2.  Insights into transcription: structure and function of single-subunit DNA-dependent RNA polymerases.

Authors:  G M Cheetham; T A Steitz
Journal:  Curr Opin Struct Biol       Date:  2000-02       Impact factor: 6.809

3.  The specificity loop of T7 RNA polymerase interacts first with the promoter and then with the elongating transcript, suggesting a mechanism for promoter clearance.

Authors:  D Temiakov; P E Mentesana; K Ma; A Mustaev; S Borukhov; W T McAllister
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

4.  Hepatitis C virus genotypes and quasispecies.

Authors:  G L Davis
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

Review 5.  Clinical significance of hepatitis C virus genotypes and quasispecies.

Authors:  P Farci; R H Purcell
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

6.  Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA-dependent RNA polymerase.

Authors:  C C Kao; X Yang; A Kline; Q M Wang; D Barket; B A Heinz
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.

Authors:  G Luo; R K Hamatake; D M Mathis; J Racela; K L Rigat; J Lemm; R J Colonno
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase.

Authors:  W Zhong; E Ferrari; C A Lesburg; D Maag; S K Ghosh; C E Cameron; J Y Lau; Z Hong
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

10.  Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.

Authors:  Bichitra K Biswal; Maia M Cherney; Meitian Wang; Laval Chan; Constantin G Yannopoulos; Darius Bilimoria; Olivier Nicolas; Jean Bedard; Michael N G James
Journal:  J Biol Chem       Date:  2005-03-02       Impact factor: 5.157

View more
  24 in total

1.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 2.  Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.

Authors:  Karina Salvatierra; Sabrina Fareleski; Alicia Forcada; F Xavier López-Labrador
Journal:  World J Virol       Date:  2013-02-12

3.  Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients.

Authors:  Qing Yang; Yuyang Ding; Fengling Feng; Enxiang Pan; Xiaozhen Fan; Xiuchang Ma; Ling Chen; Junling Zhao; Caijun Sun
Journal:  Medchemcomm       Date:  2017-07-25       Impact factor: 3.597

4.  Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Izuru Ando; Tsuyoshi Adachi; Naoki Ogura; Yukiyo Toyonaga; Kazuyuki Sugimoto; Hiroyuki Abe; Masafumi Kamada; Toru Noguchi
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

5.  In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Stephanie T Shi; Koleen J Herlihy; Joanne P Graham; Shella A Fuhrman; Chau Doan; Hans Parge; Michael Hickey; Jingjin Gao; Xiu Yu; Fannie Chau; Javier Gonzalez; Hui Li; Cristina Lewis; Amy K Patick; Rohit Duggal
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

6.  A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.

Authors:  Sreedhar Chinnaswamy; Ian Yarbrough; Satheesh Palaninathan; C T Ranjith Kumar; Vinodhini Vijayaraghavan; Borries Demeler; Stanley M Lemon; James C Sacchettini; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

7.  Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).

Authors:  Mike Flint; Stanley Mullen; Anne M Deatly; Wei Chen; Lynn Z Miller; Robert Ralston; Colin Broom; Emilio A Emini; Anita Y M Howe
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

8.  Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site.

Authors:  Dinesh Manvar; Kamlendra Singh; Virendra N Pandey
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

9.  Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.

Authors:  Yi Zhou; Doug J Bartels; Brian L Hanzelka; Ute Müh; Yunyi Wei; Hui-May Chu; Ann M Tigges; Debra L Brennan; B Govinda Rao; Lora Swenson; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

10.  Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Stephanie T Shi; Koleen J Herlihy; Joanne P Graham; Jim Nonomiya; Sadayappan V Rahavendran; Heather Skor; Rebecca Irvine; Susan Binford; John Tatlock; Hui Li; Javier Gonzalez; Angelica Linton; Amy K Patick; Cristina Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.